<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35406766</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2073-4409</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cells</Title>
          <ISOAbbreviation>Cells</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Inhibitory Effect of Selected D<sub>2</sub> Dopaminergic Receptor Agonists on VEGF-Dependent Neovascularization in Zebrafish Larvae: Potential New Therapy in Ophthalmic Diseases.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">1202</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11071202</ELocationID>
        <Abstract>
          <AbstractText>Pathological angiogenesis is correlated with many ophthalmic diseases. The most common are exudative age-related macular degeneration and proliferative diabetic retinopathy. The current treatment for these diseases is based on regularly administered anti-VEGF antibodies injections. In the study, we investigated selected D<sub>2</sub> dopaminergic receptor agonists, namely bromocriptine, cabergoline and pergolide, on hypoxia-induced neovascularization. We used the zebrafish laboratory model, specifically three-day post fertilization (dpf) Tg(<i>fli</i>-<i>1</i>: EGFP) zebrafish larvae. To induce abnormal angiogenesis of hyaloid-retinal vessels (HRVs) and intersegmental vessels (ISVs), the larvae were treated with cobalt chloride (II) (CoCl<sub>2</sub>) (a hypoxia-inducing agent) from 24 h post fertilization. The inhibitory role of D<sub>2</sub> dopaminergic receptor agonists was investigated using confocal microscopy and qPCR. Additionally, the results were compared to those obtained in the group treated with CoCl<sub>2</sub> followed by bevacizumab, the well-known antiangiogenic agent. Confocal microscopy analyses revealed severe deformation of vessels in the CoCl<sub>2</sub> treated group, while co-incubation with bromocriptine, cabergoline, pergolide and bevacizumab, respectively, significantly inhibited abnormalities of angiogenesis. The qPCR analyses supported the protective role of the chosen dopaminergic agonists by demonstrating their influence on CoCl<sub>2</sub>-derived upregulation of <i>vegfaa</i> expression. The present results suggest that the D<sub>2</sub> receptor agonists can be considered as a new direction in research for antiangiogenic therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kasica</LastName>
            <ForeName>Natalia</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0002-0242-2587</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Animal Anatomy, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 13 Street, Box 105J, 10-719 Olsztyn, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Święch</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Retina and Vitreus Surgery, Medical University in Lublin, Chmielna 1 Street, 20-079 Lublin, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saładziak</LastName>
            <ForeName>Katarzyna</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Retina and Vitreus Surgery, Medical University in Lublin, Chmielna 1 Street, 20-079 Lublin, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mackiewicz</LastName>
            <ForeName>Jerzy</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Retina and Vitreus Surgery, Medical University in Lublin, Chmielna 1 Street, 20-079 Lublin, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Osęka</LastName>
            <ForeName>Maciej</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-8017-3432</Identifier>
            <AffiliationInfo>
              <Affiliation>Oftalabs Sp. z o.o., Wrocławska 130, 58-306 Wałbrzych, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cells</MedlineTA>
        <NlmUniqueID>101600052</NlmUniqueID>
        <ISSNLinking>2073-4409</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>24MJ822NZ9</RegistryNumber>
          <NameOfSubstance UI="D010479">Pergolide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
          <NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3A64E3G5ZO</RegistryNumber>
          <NameOfSubstance UI="D001971">Bromocriptine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LL60K9J05T</RegistryNumber>
          <NameOfSubstance UI="D000077465">Cabergoline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001971" MajorTopicYN="N">Bromocriptine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077465" MajorTopicYN="N">Cabergoline</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018491" MajorTopicYN="Y">Dopamine Agonists</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007814" MajorTopicYN="N">Larva</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010479" MajorTopicYN="N">Pergolide</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015027" MajorTopicYN="Y">Zebrafish</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">D2 dopaminergic receptor agonist</Keyword>
        <Keyword MajorTopicYN="Y">angiogenesis</Keyword>
        <Keyword MajorTopicYN="Y">bromocriptine</Keyword>
        <Keyword MajorTopicYN="Y">cabergoline</Keyword>
        <Keyword MajorTopicYN="Y">hyaloid-retinal vessels (HRVs)</Keyword>
        <Keyword MajorTopicYN="Y">intersegmental vessels (ISVs)</Keyword>
        <Keyword MajorTopicYN="Y">pergolide</Keyword>
        <Keyword MajorTopicYN="Y">vascular endothelial growth factor</Keyword>
        <Keyword MajorTopicYN="Y">zebrafish</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>1</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35406766</ArticleId>
        <ArticleId IdType="pmc">PMC8997652</ArticleId>
        <ArticleId IdType="doi">10.3390/cells11071202</ArticleId>
        <ArticleId IdType="pii">cells11071202</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Maniscalco P.W.M., D’Angio C.T.  Encyclopedia of Respiratory Medicine. Elsevier; Amsterdam, The Netherlands: 2006. Vascular endothelial growth factor; pp. 413–418.</Citation>
        </Reference>
        <Reference>
          <Citation>Apte R.S., Chen D.S., Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176:1248–1264. doi: 10.1016/j.cell.2019.01.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2019.01.021</ArticleId>
            <ArticleId IdType="pmc">PMC6410740</ArticleId>
            <ArticleId IdType="pubmed">30849371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campochiaro P.A. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog. Retin. Eye Res. 2015;49:67–81. doi: 10.1016/j.preteyeres.2015.06.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.preteyeres.2015.06.002</ArticleId>
            <ArticleId IdType="pmc">PMC4651818</ArticleId>
            <ArticleId IdType="pubmed">26113211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartnett M.E. Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor. Am. J. Ophthalmol. 2020;218:208–213. doi: 10.1016/j.ajo.2020.05.025. Erratum in Am. J. Ophthalmol.
2021, 231, 213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajo.2020.05.025</ArticleId>
            <ArticleId IdType="pmc">PMC7529736</ArticleId>
            <ArticleId IdType="pubmed">32450064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen P.J., Wan L., Lai J.N., Chen C.S., Chen J.J., Yen W.M., Chiu L.T., Hu K.C., Tien P.T., Lin H.J. Increased risk of Parkinson’s disease among patients with age-related macular degeneration. BMC Ophthalmol. 2021;21:426.  doi: 10.1186/s12886-021-02196-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12886-021-02196-8</ArticleId>
            <ArticleId IdType="pmc">PMC8662906</ArticleId>
            <ArticleId IdType="pubmed">34886822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brilliant M.H., Vaziri K., Connor T.B., Jr., Schwartz S.G., Carroll J.J., McCarty C.A., Schrodi S.J., Hebbring S.J., Kishor K.S., Flynn H.W., Jr., et al.  Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration. Am. J. Med. 2016;129:292–298. doi: 10.1016/j.amjmed.2015.10.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjmed.2015.10.015</ArticleId>
            <ArticleId IdType="pmc">PMC4841631</ArticleId>
            <ArticleId IdType="pubmed">26524704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang H., Mourad S.M., Wang A., Zhai S.D., Hart R.J. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst. Rev. 2021;4:CD008605. doi: 10.1002/14651858.CD008605.pub3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD008605.pub3</ArticleId>
            <ArticleId IdType="pmc">PMC8092425</ArticleId>
            <ArticleId IdType="pubmed">33851429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herbert R.C., Thompson D.L., Mitcham P.B., Lestelle J.D., Gilley R.M., Burns P.J. Inhibitory Effects of Pergolide and Cabergoline Formulations on Daily Plasma Prolactin Concentrations in Geldings and on the Daily Prolactin Responses to a Small Dose of Sulpiride in Mares. J. Equine Vet. Sci. 2013;33:773–778. doi: 10.1016/j.jevs.2012.12.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jevs.2012.12.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonuccelli U., Colzi A., Del Dotto P. Pergolide in the treatment of patients with early and advanced Parkinson’s disease. Clin. Neuropharmacol. 2002;25:1–10. doi: 10.1097/00002826-200201000-00001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00002826-200201000-00001</ArticleId>
            <ArticleId IdType="pubmed">11852289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chávez M.N., Aedo G., Fierro F.A., Allende M.L., Egaña J.T. Zebrafish as an Emerging Model Organism to Study Angiogenesis in Development and Regeneration. Front. Physiol. 2016;7:56. doi: 10.3389/fphys.2016.00056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphys.2016.00056</ArticleId>
            <ArticleId IdType="pmc">PMC4781882</ArticleId>
            <ArticleId IdType="pubmed">27014075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiong J.W. Molecular and developmental biology of the hemangioblast. Dev. Dyn. 2008;237:1218–1231. doi: 10.1002/dvdy.21542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dvdy.21542</ArticleId>
            <ArticleId IdType="pmc">PMC3085530</ArticleId>
            <ArticleId IdType="pubmed">18429046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eberlein J., Herdt L., Malchow J., Rittershaus A., Baumeister S., Helker C.S. Molecular and Cellular Mechanisms of Vascular Development in Zebrafish. Life. 2021;11:1088.  doi: 10.3390/life11101088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/life11101088</ArticleId>
            <ArticleId IdType="pmc">PMC8539546</ArticleId>
            <ArticleId IdType="pubmed">34685459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimmel C.B., Ballard W.W., Kimmel S.R., Ullmann B., Schilling T.F. Stages of embryonic development of the zebrafish. Dev. Dyn. 1995;203:253–310. doi: 10.1002/aja.1002030302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/aja.1002030302</ArticleId>
            <ArticleId IdType="pubmed">8589427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kasica N., Jakubowski P., Kaleczyc J. P-Glycoprotein Inhibitor Tariquidar Plays an Important Regulatory Role in Pigmentation in Larval Zebrafish. Cells. 2021;10:690.  doi: 10.3390/cells10030690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells10030690</ArticleId>
            <ArticleId IdType="pmc">PMC8003715</ArticleId>
            <ArticleId IdType="pubmed">33804686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J., Gao B., Zhang W., Qian Z., Xiang Y. Monitoring antiangiogenesis of bevacizumab in zebrafish. Drug Des. Dev. Ther. 2018;12:2423–2430. doi: 10.2147/DDDT.S166330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/DDDT.S166330</ArticleId>
            <ArticleId IdType="pmc">PMC6084084</ArticleId>
            <ArticleId IdType="pubmed">30122900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y.C., Chang C.Y., Kao A., Hsi B., Lee S.H., Chen Y.H., Wang I.J. Hypoxia-induced retinal neovascularization in zebrafish embryos: A potential model of retinopathy of prematurity. PLoS ONE. 2015;10:e0126750.  doi: 10.1371/journal.pone.0126750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0126750</ArticleId>
            <ArticleId IdType="pmc">PMC4433197</ArticleId>
            <ArticleId IdType="pubmed">25978439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O’Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., et al.  C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107:43–54. doi: 10.1016/S0092-8674(01)00507-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(01)00507-4</ArticleId>
            <ArticleId IdType="pubmed">11595184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan Y., Hilliard G., Ferguson T., Millhorn D.E. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J. Biol. Chem. 2003;278:15911–15916. doi: 10.1074/jbc.M300463200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M300463200</ArticleId>
            <ArticleId IdType="pubmed">12606543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muñoz-Sánchez J., Chánez-Cárdenas M.E. The use of cobalt chloride as a chemical hypoxia model. J. Appl. Toxicol. 2019;39:556–570. doi: 10.1002/jat.3749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jat.3749</ArticleId>
            <ArticleId IdType="pubmed">30484873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J., Ke X., Wang W., Zhang H., Ma N., Fu W., Zhao M., Gao X., Hao X., Zhang Z. Aloe-emodin suppresses hypoxia-induced retinal angiogenesis via inhibition of HIF-1α/VEGF pathway. Int. J. Biol. Sci. 2016;12:1363–1371. doi: 10.7150/ijbs.16334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijbs.16334</ArticleId>
            <ArticleId IdType="pmc">PMC5118782</ArticleId>
            <ArticleId IdType="pubmed">27877088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alvarez Y., Astudillo O., Jensen L., Reynolds A.L., Waghorne N., Brazil D.P., Cao Y., O’Connor J.J., Kennedy B.N. Selective inhibition of retinal angiogenesis by targeting PI3 kinase. PLoS ONE. 2009;4:e7867.  doi: 10.1371/journal.pone.0007867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0007867</ArticleId>
            <ArticleId IdType="pmc">PMC2773410</ArticleId>
            <ArticleId IdType="pubmed">19924235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chimote G., Sreenivasan J., Pawar N., Subramanian J., Sivaramakrishnan H., Sharma S. Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery. Drug Des. Dev. Ther. 2014;8:1107–11023. doi: 10.2147/DDDT.S55621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/DDDT.S55621</ArticleId>
            <ArticleId IdType="pmc">PMC4145829</ArticleId>
            <ArticleId IdType="pubmed">25170251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakroborty D., Sarkar C., Mitra R.B., Banerjee S., Dasgupta P.S., Basu S. Depleted dopamine in gastric cancer tissues: Dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin. Cancer Res. 2004;10:4349–4356. doi: 10.1158/1078-0432.CCR-04-0059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-04-0059</ArticleId>
            <ArticleId IdType="pubmed">15240521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basu S., Dasgupta P.S. Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue. Dig. Dis. Sci. 1999;44:916–921. doi: 10.1023/A:1026644110737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1026644110737</ArticleId>
            <ArticleId IdType="pubmed">10235597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Enhancement of L-dopa incorporation into melanoma by dopa decarboxylase inhibition. Wick M.M., Kramer R.A., Gorman M. J. Investig. Dermatol. 1978;70:358–360. doi: 10.1111/1523-1747.ep12543559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1523-1747.ep12543559</ArticleId>
            <ArticleId IdType="pubmed">649984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakroborty D., Chowdhury U.R., Sarkar C., Baral R., Dasgupta P.S., Basu S. Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J. Clin. Investig. 2008;118:1380–1389. doi: 10.1172/JCI33125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI33125</ArticleId>
            <ArticleId IdType="pmc">PMC2267013</ArticleId>
            <ArticleId IdType="pubmed">18340382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreno-Smith M., Lu C., Shahzad M.M., Pena G.N., Allen J.K., Stone R.L., Mangala L.S., Han H.D., Kim H.S., Farley D., et al.  Dopamine blocks stress-mediated ovarian carcinoma growth. Clin. Cancer Res. 2011;17:3649–3659. doi: 10.1158/1078-0432.CCR-10-2441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-2441</ArticleId>
            <ArticleId IdType="pmc">PMC3107884</ArticleId>
            <ArticleId IdType="pubmed">21531818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Senogles S.E. D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69. Anti-Cancer Drugs. 2007;18:801–807. doi: 10.1097/CAD.0b013e3280b10d36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CAD.0b013e3280b10d36</ArticleId>
            <ArticleId IdType="pubmed">17581302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy S., Lu K., Nayak M.K., Bhuniya A., Ghosh T., Kundu S., Ghosh S., Baral R., Dasgupta P.S., Basu S. Activation of D2 Dopamine Receptors in CD133+ve Cancer Stem Cells in Non-small Cell Lung Carcinoma Inhibits Proliferation, Clonogenic Ability, and Invasiveness of These Cells. J. Biol. Chem. 2017;292:435–445. doi: 10.1074/jbc.M116.748970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M116.748970</ArticleId>
            <ArticleId IdType="pmc">PMC5241722</ArticleId>
            <ArticleId IdType="pubmed">27920206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakroborty D., Sarkar C., Yu H., Wang J., Liu Z., Dasgupta P.S., Basu S. Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells. Proc. Natl. Acad. Sci. USA. 2011;108:20730–20735. doi: 10.1073/pnas.1108696108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1108696108</ArticleId>
            <ArticleId IdType="pmc">PMC3251052</ArticleId>
            <ArticleId IdType="pubmed">22143796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chauvet N., Romanò N., Lafont C., Guillou A., Galibert E., Bonnefont X., Le Tissier P., Fedele M., Fusco A., Mollard P., et al.  Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model. Int. J. Cancer. 2017;140:2150–2161. doi: 10.1002/ijc.30628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.30628</ArticleId>
            <ArticleId IdType="pubmed">28152577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrero H., García-Pascual C.M., Gómez R., Delgado-Rosas F., Cauli O., Simón C., Gaytán F., Pellicer A. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro: Implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists. Fertil. Steril. 2014;101:1411–1418. doi: 10.1016/j.fertnstert.2014.01.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2014.01.031</ArticleId>
            <ArticleId IdType="pubmed">24581579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basu S., Nagy J.A., Pal S., Vasile E., Eckelhoefer I.A., Bliss V.S., Manseau E.J., Dasgupta P.S., Dvorak H.F., Mukhopadhyay D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat. Med. 2001;7:569–574. doi: 10.1038/87895.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/87895</ArticleId>
            <ArticleId IdType="pubmed">11329058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarkar C., Chakroborty D., Mitra R.B., Banerjee S., Dasgupta P.S., Basu S. Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2004;287:H1554–H1560. doi: 10.1152/ajpheart.00272.2004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpheart.00272.2004</ArticleId>
            <ArticleId IdType="pubmed">15371263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha S., Vohra P.K., Bhattacharya R., Dutta S., Sinha S., Mukhopadhyay D. Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Src-homology-2-domain-containing protein tyrosine phosphatase 2. J. Cell Sci. 2009;122 Pt 18:3385–3392. doi: 10.1242/jcs.053124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.053124</ArticleId>
            <ArticleId IdType="pmc">PMC2736867</ArticleId>
            <ArticleId IdType="pubmed">19706677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Büchler P., Reber H.A., Büchler M.W., Friess H., Lavey R.S., Hines O.J. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer. 2004;100:201–210. doi: 10.1002/cncr.11873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.11873</ArticleId>
            <ArticleId IdType="pubmed">14692041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beckert S., Farrahi F., Perveen Ghani Q., Aslam R., Scheuenstuhl H., Coerper S., Königsrainer A., Hunt T.K., Hussain M.Z. IGF-I-induced VEGF expression in HUVEC involves phosphorylation and inhibition of poly(ADP-ribose)polymerase. Biochem. Biophys. Res. Commun. 2006;341:67–72. doi: 10.1016/j.bbrc.2005.12.148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2005.12.148</ArticleId>
            <ArticleId IdType="pubmed">16412381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narburgh L.J., Turner J., Freeman S.J. Evaluation of the teratogenic potential of the dopamine agonist bromocriptine in rats. Toxicol. Lett. 1990;50:189–194. doi: 10.1016/0378-4274(90)90010-J.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0378-4274(90)90010-J</ArticleId>
            <ArticleId IdType="pubmed">2309237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turkalj I., Braun P., Krupp P. Surveillance of bromocriptine in pregnancy. JAMA. 1982;247:1589–1591. doi: 10.1001/jama.1982.03320360039028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.1982.03320360039028</ArticleId>
            <ArticleId IdType="pubmed">7062462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caccavelli L., Cussac D., Pellegrini I., Audinot V., Jaquet P., Enjalbert A. D2 dopaminergic receptors: Normal and abnormal transduction mechanisms. Horm. Res. 1992;38:78–83. doi: 10.1159/000182494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000182494</ArticleId>
            <ArticleId IdType="pubmed">1306522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuttfeld E., Ballmer-Hofer K. Structure and function of VEGF receptors. IUBMB Life. 2009;61:915–922. doi: 10.1002/iub.234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/iub.234</ArticleId>
            <ArticleId IdType="pubmed">19658168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumoto K., Ema M. Roles of VEGF-A signalling in development, regeneration, and tumours. J. Biochem. 2014;156:1–10. doi: 10.1093/jb/mvu031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jb/mvu031</ArticleId>
            <ArticleId IdType="pubmed">24839295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ober E.A., Olofsson B., Mäkinen T., Jin S.W., Shoji W., Koh G.Y., Alitalo K., Stainier D.Y. Vegfc is required for vascular development and endoderm morphogenesis in zebrafish. EMBO Rep. 2004;5:78–84. doi: 10.1038/sj.embor.7400047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.embor.7400047</ArticleId>
            <ArticleId IdType="pmc">PMC1298958</ArticleId>
            <ArticleId IdType="pubmed">14710191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rezzola S., Belleri M., Gariano G., Ribatti D., Costagliola C., Semeraro F., Presta M. In vitro and ex vivo retina angiogenesis assays. Angiogenesis. 2014;17:429–442. doi: 10.1007/s10456-013-9398-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10456-013-9398-x</ArticleId>
            <ArticleId IdType="pubmed">24121991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khaliq A., Dunk C., Jiang J., Shams M., Li X.F., Acevedo C., Weich H., Whittle M., Ahmed A. Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: Molecular evidence for “placental hyperoxia” in intrauterine growth restriction. Lab. Investig. 1999;79:151–170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10068204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poole T.J., Finkelstein E.B., Cox C.M. The role of FGF and VEGF in angioblast induction and migration during vascular development. Dev. Dyn. 2001;220:1–17. doi: 10.1002/1097-0177(2000)9999:9999&lt;::AID-DVDY1087&gt;3.0.CO;2-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1097-0177(2000)9999:9999&lt;::AID-DVDY1087&gt;3.0.CO;2-2</ArticleId>
            <ArticleId IdType="pubmed">11146503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia T., Jacquet T., Dalonneau F., Coudert P., Vaganay E., Exbrayat-Héritier C., Vollaire J., Josserand V., Ruggiero F., Coll J.L., et al.  FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells. BMC Biol. 2021;19:173.  doi: 10.1186/s12915-021-01103-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12915-021-01103-3</ArticleId>
            <ArticleId IdType="pmc">PMC8390225</ArticleId>
            <ArticleId IdType="pubmed">34433435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Javerzat S., Auguste P., Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol. Med. 2002;8:483–489. doi: 10.1016/S1471-4914(02)02394-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1471-4914(02)02394-8</ArticleId>
            <ArticleId IdType="pubmed">12383771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conte C., Riant E., Toutain C., Pujol F., Arnal J.F., Lenfant F., Prats A.C. FGF2 translationally induced by hypoxia is involved in negative and positive feedback loops with HIF-1alpha. PLoS ONE. 2008;3:e3078.  doi: 10.1371/journal.pone.0003078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0003078</ArticleId>
            <ArticleId IdType="pmc">PMC2518102</ArticleId>
            <ArticleId IdType="pubmed">18728783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kakudo N., Morimoto N., Ogawa T., Taketani S., Kusumoto K. Hypoxia Enhances Proliferation of Human Adipose-Derived Stem Cells via HIF-1ɑ Activation. PLoS ONE. 2015;10:e0139890.  doi: 10.1371/journal.pone.0139890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0139890</ArticleId>
            <ArticleId IdType="pmc">PMC4605777</ArticleId>
            <ArticleId IdType="pubmed">26465938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mingyuan X., Qianqian P., Shengquan X., Chenyi Y., Rui L., Yichen S., Jinghong X. Hypoxia-inducible factor-1α activates transforming growth factor-β1/Smad signaling and increases collagen deposition in dermal fibroblasts. Oncotarget. 2017;9:3188–3197. doi: 10.18632/oncotarget.23225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.23225</ArticleId>
            <ArticleId IdType="pmc">PMC5790456</ArticleId>
            <ArticleId IdType="pubmed">29423039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marques I.J., Leito J.T., Spaink H.P., Testerink J., Jaspers R.T., Witte F., van den Berg S., Bagowski C.P. Transcriptome analysis of the response to chronic constant hypoxia in zebrafish hearts. J. Comp. Physiol. B. 2008;178:77–92. doi: 10.1007/s00360-007-0201-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00360-007-0201-4</ArticleId>
            <ArticleId IdType="pmc">PMC2200676</ArticleId>
            <ArticleId IdType="pubmed">17828398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheid A., Wenger R.H., Christina H., Camenisch I., Ferenc A., Stauffer U.G., Gassmann M., Meuli M. Hypoxia-regulated gene expression in fetal wound regeneration and adult wound repair. Pediatr. Surg. Int. 2000;16:232–236. doi: 10.1007/s003830050735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s003830050735</ArticleId>
            <ArticleId IdType="pubmed">10898220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khaidakov M., Szwedo J., Mitra S., Mehta J.L. Angiostatic effects of aspirin in hypoxia-reoxygenation are linked to modulation of TGFβ1 signaling. J. Cardiovasc. Pharmacol. Ther. 2011;16:105–110. doi: 10.1177/1074248410378505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1074248410378505</ArticleId>
            <ArticleId IdType="pubmed">20940449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eme J., Rhen T., Tate K.B., Gruchalla K., Kohl Z.F., Slay C.E., Crossley D.A., 2nd Plasticity of cardiovascular function in snapping turtle embryos (Chelydra serpentina): Chronic hypoxia alters autonomic regulation and gene expression. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013;304:R966–R979. doi: 10.1152/ajpregu.00595.2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpregu.00595.2012</ArticleId>
            <ArticleId IdType="pubmed">23552497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohta K., Kuno S., Mizuta I., Fujinami A., Matsui H., Ohta M. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes. Life Sci. 2003;73:617–626. doi: 10.1016/S0024-3205(03)00321-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0024-3205(03)00321-7</ArticleId>
            <ArticleId IdType="pubmed">12770616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rezzola S., Paganini G., Semeraro F., Presta M., Tobia C. Zebrafish (Danio rerio) embryo as a platform for the identification of novel angiogenesis inhibitors of retinal vascular diseases. Biochim. Biophys. Acta. 2016;1862:1291–1296. doi: 10.1016/j.bbadis.2016.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2016.04.009</ArticleId>
            <ArticleId IdType="pubmed">27085972</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
